Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I. by Jones, J. I. et al.
Proc. Nati. Acad. Sci. USA
Vol. 88, pp. 7481-7485, September 1991
Medical Sciences
Phosphorylation of insulin-like growth factor (IGF)-binding protein
1 in cell culture and in vivo: Effects on affinity for IGF-I
(Chinese hamster ovary cells/hepatoma ceils/decidual cells/amniotic fluid/non-SDS polyacrylamide gel electrophoresis)
JOHN I. JONES*, A. JOSEPH D'ERCOLEt, CECILIA CAMACHO-HUBNER*, AND DAVID R. CLEMMONS**
Departments of *Medicine and tPediatrics, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7170
Communicated by Dale E. Bauman, May 23, 1991 (received for review January 21, 1991)
ABSTRACT The insulin-like growth factors (IGF-I and
IGF-II) are present in extracellular fluids bound to specific
IGF-binding proteins (IGFBPs). We and others have reported
varying biologic activity of different preparations of IGFBP-1
that appeared to have identical amino acid sequences and
molecular sizes. This observation prompted us to determine
whether IGFBP-1 undergoes posttranslational modifications.
Immunoprecipitation was used to show that Chinese hamster
ovary cells (transfected with a human IGFBP-l cDNA con-
struct) and human hepatoma (HepG2) cells secrete 32P-labeled
IGFBP-1 following incubation with [32P orthophosphate. Phos-
pho amino acid analysis of 32P-labeled IGFBP-l revealed only
phosphoserine residues. A method was developed that could
separate nonphosphorylated IGFBP-l from four or five phos-
phorylated isoforms. Using this technique we demonstrated
that human amniotic fluid and human fetal serum contain a
large proportion of nonphosphorylated IGFBP-1, as well as
phosphorylated forms. In contrast, HepG2 cells and human
decidual cells secrete predominantly the phosphorylated iso-
forms. These observations suggest that IGFBP-1 is secreted as
a phosphoprotein and is subsequently dephosphorylated in
vivo. Binding studies showed that the phosphorylated IGFBP-1
secreted by HepG2 cells has a 6-fold higher affinity for IGF-I
than it does after dephosphorylation. We conclude that
IGFBP-1 is phosphorylated and that this phosphorylation is a
physiologically important posttranslational modification.
The insulin-like growth factors (IGF-I and IGF-II) are present
in plasma and other extracellular fluids bound to specific
IGF-binding proteins (IGFBPs). Our laboratory has demon-
strated that a specific form of IGFBP derived from human
amniotic fluid, designated IGFBP-1 (1), potentiates the mi-
togenic activity of IGF-I in smooth muscle cells and fibro-
blasts in culture (2). Not all ofour IGFBP-1 preparations have
demonstrated equivalent biologic activity, and other labora-
tories, using various biologic test systems, have reported that
IGFBP-1 inhibits the effects of IGF-I. Specifically, IGFBP-1
has been found to inhibit IGF-I stimulation of cell growth (3,
4) or differentiated cellular functions, such as amino acid
transport (4). In addition, differing estimates ofthe affinity of
IGFBP-1 for IGF-I have been reported (5-7), suggesting that
the purified preparations have not been truly homogeneous.
It has been proposed that an unidentified posttranslational
modification may account for these differences in biologic
activity and binding characteristics (6). To date the only
posttranslational modification reported has been the capacity
of IGFBP-1 from amniotic fluid to form disulfide-linked
multimers (7). The current studies were initiated to determine
whether IGFBP-1 might be phosphorylated, whether phos-
phorylated IGFBP-1 could be detected in cell culture super-
natants and in physiologic fluids, and whether phosphoryla-
tion resulted in alterations of the binding affinity of IGFBP-1
for IGF-I.
MATERIALS AND METHODS
Materials. Chinese hamster ovary (CHO-Ki) cells and
human hepatoma (HepG2) cells were obtained from the
American Type Culture Collection. Conditioned medium
from primary cultures of human decidual cells (8) was a gift
from Stuart Handwerger. IGFBP-1 was purified from human
amniotic fluid (6). Recombinant human IGFBP-1 from a
bacterial source was a gift from Synergen (Boulder, CO).
Human fetal serum was obtained at 20 weeks ofgestation (9).
Rabbit antiserum specific for human IGFBP-1 was prepared
as described (10). Recombinant IGF-I was a gift from Ge-
nentech. [32P]Orthophosphoric acid (8500-9120 Ci/mmol; 1
Ci = 37 GBq) was purchased from NEN and [-32P]ATP
(3000 Ci/mmol) from Amersham. Poly(vinylidene difluoride)
(PVDF) transfer membranes were obtained from Millipore.
All other chemicals were purchased from Sigma.
Transfection of CHO Cells. An expression vector contain-
ing the cDNA for the protein-coding region of human
IGFBP-1 was constructed by ligating a human IGFBP-1
cDNA (bases 1-933; ref. 11) into a pUC18-derived plasmid,
pNUT (the generous gift of Richard D. Palmiter, University
of Washington, Seattle), so that the cDNA was driven by the
mouse metallothionein promoter and utilized polyadenylyla-
tion signals and sites derived from the human growth hor-
mone gene. pNUT also contains the gene for dihydrofolate
reductase driven by the simian virus 40 promoter, allowing
selection of cellular transfectants with methotrexate. CHO
cells were transfected with the expression vector by calcium
phosphate precipitation followed by glycerol shock (12).
Stable methotrexate-resistant cell lines were established. The
cell line (designated CHOBP1-A6) secreting the greatest
amount of human IGFBP-1 was used in phosphorylation
experiments.
Phosphorylation and Immunoprecipitation of IGFBP-1.
Transfected CHOBP1-A6 cells and HepG2 human hepatoma
cells were grown to confluency on 10-cm tissue culture
dishes. The cell monolayers were incubated for 5 hr in 5 ml
of phosphate-free Eagle's minimal essential medium (MEM)
containing 250 ,uCi of 32p;, and conditioned media were
collected. The cells were extracted for 30 min at 25°C with
0.5% Triton X-100 in 5 ml of phosphate-buffered saline with
5 mM ATP, 10 mM NaF, 1 mM phenylmethylsulfonyl fluo-
ride, and 1 mM benzamidine hydrochloride. Aliquots (1 ml)
of conditioned media and cell lysates were incubated in
siliconized tubes at 4°C with a 1:1000 dilution of rabbit
polyclonal antiserum to cell human IGFBP-1. After overnight
incubation, 8 ,1l of an ovine antiserum to rabbit IgG was
added to all tubes and incubated 1 hr at 4°C. Antibody-bound
Abbreviations: IGF, insulin-like growth factor; IGFBP, IGF-binding
protein; PVDF, poly(vinylidene difluoride).
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IGFBP-1 was separated by centrifugation at 8000 x g for 20
min. The immunoprecipitated proteins were resolved by
SDS/12.5% PAGE.
To determine whether an ectokinase was present on cell
surfaces, confluent monolayers of transfected CHOBP1-A6
cells in 2-cm2 wells were incubated in 0.5 ml of MEM (not
phosphate-free) with test substances and 5 ,uCi of
[y-32P]ATP, 0.01% bovine serum albumin, 1 mM MnC12, and
20 mM Hepes (pH 7.4). After 30 min at 37TC, phosphorylation
was terminated by the addition of 0.25 ml of phosphate-
buffered saline at 40C with 2 mM unlabeled ATP. Immuno-
precipitation was immediately performed at 40C for some
media samples as described above, and other samples were
precipitated at 40C with 15% (wt/vol) trichloroacetic acid.
PAGE in the Absence of SDS. Non-SDS PAGE was per-
formed in 5 cm x 8 cm x 1.5 mm slab gels in a minigel
apparatus (Hoefer). A discontinuous buffer system was used,
with acrylamide concentrations of 10% in the resolving gel
and 4% in the stacking gel. The resolving gel was buffered to
pH 7.5 with 100 mM Tris'HCl, and the stacking gel to pH 5.5
with 70 mM Tris-HPO4. Both the stacking and the resolving
gel contained a nonionic detergent, n-octyl glucoside, at 20
mM. Sample buffer (170 mM Tris-HPO4, pH 5.5/90 mM
n-octyl glucoside/40% glycerol/0.008% bromphenol blue)
was added to all samples in a 1:3 ratio. Electrophoresis was
performed at 25°C with tap water cooling. The cathode buffer
contained 3 g of Tris and 2 g ofglycylglycine per liter (pH 8.1),
and the anode buffer contained 50mM Tris-HCI (pH 8.1). The
gels were run at constant current: 10 mA per gel while
stacking and 25 mA per gel while resolving. The proteins
were transferred to PVDF membranes by electroblotting
(13). The transfer membranes were then subjected to auto-
radiography, in the case of 32P-containing samples, and/or
Western blotting by probing with either 1251I-labeled IGF-I
(150;000 cpm/ml, visualized by autoradiography) or rabbit
antiserum to human IGFBP-1 (1:1000 dilution, visualized
using an alkaline phosphatase-linked anti-rabbit IgG from
Sigma and a phosphatase-dependent color development sys-
tem from Promega) as described (10, 13, 14).
Assay of Binding of IGFBP-1 to IGF-I. To determine the
binding affinities of phosphorylated and nonphosphorylated
IGFBP-1 for IGF-I, 125I-labeled recombinant IGF-1 (15)
(25,000 cpm; specific activity, 300 ,uCi/,ug) was incubated
with IGFBP-1 (4 ng/ml) from three sources. IGFBP-1 was
purified from a recombinant bacterial source, HepG2 condi-
tioned medium, and human amniotic fluid (6). The HepG2-
derived IGFBP-1 was purified from conditioned medium by
phenyl-Sepharose chromatography followed by HPLC (Vy-
dac C4 column). Two micrograms of the purified HepG2
protein was dephosphorylated by incubation with 12 units of
Escherichia coli alkaline phosphatase (Sigma) at 37°C for 30
hr. The dephosphorylated protein was repurified by HPLC
on a C4 column. All four preparations of IGFBP-1 were
shown to be homogeneous by SDS/PAGE with silver stain-
ing. IGFBP-1 and labeled IGF-I were incubated in triplicate
overnight at 4°C in 0.25 ml of 0.1 M Hepes/44 mM NaH2PO4/
0.01% Triton X-100/0.1% bovine serum albumin/0.02%
NaN3, pH 6.0), in the presence of unlabeled recombinant
IGF-I (0-40 ng/ml). Bound label was separated from free by
precipitation in 12.5% polyethylene glycol (6, 16). Nonspe-
cific binding was determined by measuring bound 125I-IGF-I
in the presence of unlabeled IGF-I (1 ,ug/ml). Nonspecific
binding constituted <25% of bound radiolabel in the absence
of unlabeled IGF-I and <15% of the total amount of radio-
label added to each tube.
RESULTS
Secretion of Phosphorylated IGFBP-1 by Cells in Culture.
The CHOBP1-A6 transfected cell line secreted human
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FIG. 1. Immunoprecipitation of IGFBP-1 from 32P-labeled con-
ditioned media of CHOBP1-A6 cells (lanes D-F) and of HepG2 cells
(lanes A-) and from 32P-labeled CHOBP1-A6 Triton cell lysates
(lanes G-I). Samples (200 jul) were immunoprecipitated with hon-
immune rabbit serum (lanes A, D, and G), IGFBP-1 antiserum (lanes
B, E, and H), or antiserum preincubated with unlabeled IGFBP-1 at
1 /Ag/ml (lanes C, F, and I). The immunoprecipitates were analyzed
by SDS/PAGE with autoradiography ofthe dried gels. A specifically
immunoprecipitated Mr 29,000 band of phosphorylated IGFBP-1 is
apparent in lanes B, E, and H. 32P-labeled CHOBP1-A6 cell layers
were also extracted directly with LAemmli sample buffer containing
2% SDS (lane J), to demonstrate total cell-associated phosphopro-
teins.
IGFBP-1 as determined by RIA and Western blotting. Hu-
man IGFBP-1 was present at a concentration of 2 pug/ml in
48-hr conditioned medium. Ligand blotting showed that
nontransfected CHO cells secreted a Mr 24,000 IGFBP. This
protein did not react with IGFBP-1 antibody (data not
shown). The transfected CHO cells secreted an additional Mr
29,000 form of IGFBP that reacted strongly with the anti-
human IGFBP-1 antibody.
Immunoprecipitation ofmedia conditioned by CHOBP1-A6
cells and by HepG2 hepatoma cells in the presence of 32p;
demonstrated a Mr 29,000 32P-labeled protein (Fig. 1, lanes B
and E). The immunoprecipitation of this band was specific,
since band intensity was diminished when an excess of unla-
beled IGFBP-1 was used (lanes C and F). This phosphoprotein
was not present in medium conditioned by nontransfected
CHO cells (data not shown). To determine which amino
acid(s) was phosphorylated, analysis of the immunoprecipi-
tated 32P-labeled IGFBP-1 was performed by two-dimensional
electrophoresis on cellulose TLC plates (17). Only phospho-
serine residues were evident (data not shown).
A phosphoprotein with identical apparent molecular
weight was also immunoprecipitated from the Triton lysate of
CHOBP1-A6 cells (Fig. 1, lane H). The location of the
phosphoprotein in the Triton lysate could have been either in
the intracellular compartment or on the external surface of
the cell membrane, and therefore the kinase responsible for
its phosphorylation could have been in either location. Ki-
nases that are similar to casein kinase II and cAMP-
dependent protein kinase and are associated with external
cell surfaces (ectokinases) have been described in both CHO
and hepatoma cells (18, §). To determine whether an ectoki-
nase might phosphorylate IGFBP-1, the transfected CHO
cells were incubated with [y-32P]ATP and exogenous unla-
beled, nonphosphorylated IGFBP-1. No IGFBP-1 was phos-
phorylated under these conditions, whether secreted by the
cells during the incubation (Fig. 2, lane E) or added exoge-
nously at the beginning of the incubation period (lanes F-H).
This was true despite the demonstration of the presence of
casein kinase activity on the surfaces of the cells under our
§Vilgrain, I. & Baird, A., Endocrine Society, 72nd Annual Meeting,
June 23, 1990, p. 1327 (abstr.).
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FIG. 2. An ectokinase on the surface of CHOBP1-A6 cells
phosphorylates casein and phosvitin but not IGFBP-1. Cells were
incubated for 30 min with [y-32P]ATP and 50 /Ag of casein (lanes A
and B), 50 jig of phosvitin (lanes C and D), 100 ng of bacterial
recombinant IGFBP-1 (lanes F-H), or with no other additives (lane
E), and the media were collected for analysis. For lanes A-F,
proteins were precipitated with 15% trichloroacetic acid; lanes G and
H contained immunoprecipitates with IGFBP-1 antiserum. Phospho-
rylated casein (Mr 30,000) is demonstrated in lane A and phospho-
rylated phosvitin (Mr 36,000) in lane C. Heparin (50 jig) was included
in lanes B and D and resulted in attenuation of casein and phosvitin
phosphorylation. Other proteins in the media were phosphorylated
by ectokinase activity, as demonstrated by the presence of multiple
other 32P-labeled bands. No phosphorylated IGFBP-1 (Mr 29,000)
was detected by either acid precipitation (lane F) or immunoprecip-
itation (lanes G and H). cAMP (100 AiM) was added to the sample for
lane H. The addition of cAMP (10 jM), cGMP (10 or 100 ,uM), or
dibutryl-cAMP (10 or 100 juM) resulted in results similar to lane H
(data not shown).
experimental conditions, as has been described forCHO cells
(19). We observed phosphorylation of casein (Fig. 2, lane A)
and phosvitin (lane C) that was suppressed by coincubation
with heparin (lanes B and D), as expected for this type of
ectokinase (20). We incubated the transfected CHO cells with
10-100 AiM cAMP (lane H) as well as cGMP and dibutryl-
cAMP (lanes not shown but similar to lane H) in the presence
of [y-32P]ATP and nonphosphorylated IGFBP-1 and were
unable to demonstrate phosphorylation of IGFBP-1 by a
cAMP-dependent ectokinase. We conclude that the phos-
phorylated IGFBP-1 we find in the cell supernatants is
phosphorylated by an intracellular kinase.
Separation of Nonphosphorylated IGFBP-1 from Phospho-
rylated Isoforms. Although immunoprecipitation demon-
strated the presence of phosphorylated IGFBP-1, this tech-
nique does not permit evaluation of the relative amounts of
phosphorylated and nonphosphorylated IGFBP-1. PAGE
was performed in the absence ofSDS in order to alter protein
migration on the basis of molecular charge as well as mass,
thus permitting separation of phosphorylated from nonphos-
phorylated IGFBP-1. In addition, the pH during the resolving
phase of electrophoresis was lowered to 8.3. The phospho-
rylated and 32P-labeled IGFBP-1 from CHOBP1-A6 cells
resolved into four bands that could be visualized by both
autoradiography and immunoblotting. A single band of non-
phosphorylated IGFBP-1 was visualized by immunoblotting
but not by autoradiography, because it contained no 32p (Fig.
3). Following exposure to alkaline phosphatase, the intensity
of the nonphosphorylated band was increased and that of the
phosphorylated bands was diminished.
Detection of Phosphorylated and Nonphosphorylated
IGFBP-1 in Human Physiologc Fluids. To determine whether
physiologic fluids and purified preparations of IGFBP-1
contained phosphorylated or nonphosphorylated forms of
IGFBP-1, other nonlabeled samples were evaluated by non-
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FIG. 3. Non-SDS PAGE of 32P-labeled conditioned medium from
CHOBP1-A6 cells. 32P-labeled conditioned medium (20 jil) was
analyzed by non-SDS PAGE after incubation for 2 hr at 37°C in the
presence or absence of 3 units of bovine intestinal alkaline phospha-
tase. After electrophoresis the proteins in the gel were transferred to
a PVDF membrane. Both an autoradiograph of the membrane and
the membrane itself after immunoblotting with IGFBP-1 antiserum
are shown. Alkaline phosphatase (arrowhead) is visible as a band on
the autoradiograph because it incorporated 32P during the incubation
period, and it is visible on the immunoblot because it reacted with the
developing reagent.
ated and nonphosphorylated forms of IGFBP-1 were dem-
onstrated. The immunoblots showed that recombinant
IGFBP-1 derived from a bacterial expression system repre-
sented a homogeneous nonphosphorylated form, whereas
IGFBP-1 secreted by HepG2 cells consisted primarily of four
or five isoforms of phosphoprotein and very little of the
nonphosphorylated protein. Human decidual cells secreted
only phosphorylated isoforms. These isoforms were con-
verted into more slowly migrating isoforms by 2 hr of
treatment with alkaline phosphatase as shown. Prolonged
treatment (8 hr) was required for complete dephosphoryla-
tion (data not shown). Human fetal serum and human amni-
otic fluid contained significant amounts of both phosphoryl-
ated and nonphosphorylated IGFBP-1 but minimal amounts
of the rapidly migrating phosphorylated isoforms. The ligand
blot (Fig. 4) demonstrated that both nonphosphorylated and
phosphorylated isoforms were capable of binding 1251-IGF-I.
Effects of IGFBP-1 Phosphorylation on Affinity for IGF-I.
To evaluate the physiologic significance of the phosphory-
lation state of IGFBP-1, we compared the IGF-I binding
affinity of phosphorylated IGFBP-1 (purified from HepG2
conditioned medium) with that of nonphosphorylated
IGFBP-1 (both the recombinant bacterial material and the
dephosphorylated HepG2 IGFBP-1) and with that of
IGFBP-1 purified from human amniotic fluid (Fig. 5). Scat-
chard plots obtained for the phosphorylated and nonphos-
phorylated forms of IGFBP-1 were linear, indicating the
presence of a single binding site. The slopes of these Scat-
chard plots were significantly different, however, and indi-
cated that the IGF-I affinity constant ofthe dephosphorylated
HepG2 IGFBP-1 (Ka = 2.8 + 0.2 x 109 M-1) was 6-fold lower
than the affinity constant of the mixture of phosphorylated
isoforms from HepG2 conditioned medium (Ka = 1.7 ± 0.2
x 1010 M-1). The affinity of the nonphosphorylated recom-
binant IGFBP-1 (Ka = 4.7 + 0.4 x 10 M- was 4-fold lower
than that of phosphorylated IGFBP-1. In contrast, the Scat-
chard plot for the IGFBP-1 purified from amniotic fluid was
curvilinear, as has been described previously (5, 6). This
result might be expected, in light ofour findings that amniotic
fluid IGFBP-1 is a combination of phosphorylated and non-
phosphorylated IGFBP-1 isoforms, with differing IGF-I bind-
ing affinities.
DISCUSSION
These studies demonstrate that IGFBP-1 undergoes phos-
phorylation, an important posttranslational modification.
Medical Sciences: Jones et al.
W-1 _9
7484 Medical Sciences: Jones et al.
MMUNOBLCF- IGAND BLC
~~~~~~~~~~~~~~~~~~~~~~~~K IS
Cell Fluid Serum :GFEP
FIG. 4. Non-SDS PAGE of unlabeled samples that contain human IGFBP-1. Decidual cell and HepG2 conditioned media (20 ELI), fetal serum
(5 ,ul), recombinant IGFBP-1 (30 ng), and human amniotic fluid IGFBP-1 (30 ng) were analyzed after incubation for 2 hr at 370C in the presence
or absence of 3 units of alkaline phosphatase. The transfer membranes after immunoblotting and an 1251-IGF-I ligand blot of the HepG2
conditioned medium are shown. The alkaline phosphatase band in the immunoblots is shown by the arrowhead. The upper band, which is
intensified by incubation with alkaline phosphatase, represents nonphosphorylated IGFBP-1. The lower four or five bands, which are attenuated
by incubation with alkaline phosphatase, represent phosphorylated isoforms of IGFBP-1.
Phosphorylation occurs not only in CHO cells transfected
with an IGFBP-1 cDNA construct but also in human hepa-
toma and decidual cells, two naturally occurring cell types.
Phosphorylation of IGFBP-1 results in sufficient alteration
in its charge density and/or conformation to result in a
change in electrophoretic mobility. Both a nonphospho-
rylated form and four or five phosphorylated isoforms can be
detected. Although the transfected CHO cell line secretes
significant quantities of the nonphosphorylated form, HepG2
cells and human decidual cells each secrete primarily phos-
phorylated forms of IGFBP-1. The immunoblots and 32P
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FIG. 5. Scatchard analysis of IGF-I binding to four forms of
IGFBP-1: nonphosphorylated recombinant (v), phosphorylated
HepG2-derived before (e) and after (o) dephosphorylation with
alkaline phosphatase, and human amniotic fluid-derived (Inset, *).
Equilibrium binding of IGFBP-1 (4 ng/ml) to 125I-IGF-I in the
presence of unlabeled IGF-I (0-40 ng/ml) was performed as de-
scribed in Materials and Methods. Symbols designate the mean
values and error bars (where larger than the symbols) show the SE
for triplicate determinations in a representative experiment. First-
order regression lines (dashed) were drawn through the recombinant
and HepG2-derived IGFBP-1 plots. The slopes ofthe regression lines
obtained from seven experiments were used to determine mean Ka
values (± SE) for HepG2-derived IGFBP-1 before (1.7 + 0.2 X 1010
M-1) and after (2.8 + 0.2 x 109 M-1) dephosphorylation and for
recombinant IGFBP-1 (4.7 + 0.4 x 109 M-1). All three Ka values
were statistically different by t test (P < 0.01).
demonstrate four distinct phosphorylated bands (one of
which suggests a doublet). In contrast, human fetal serum
and human amniotic fluid contain proportionately more ofthe
nonphosphorylated form and less of the phosphorylated
isoforms. Recombinant IGFBP-1 migrates in non-SDS-
containing gels as a single nonphosphorylated band, presum-
ably because the bacteria synthesizing it lack the kinase
required to phosphorylate the protein. The use of SDS-
containing gels to analyze IGFBP-1 in conditioned media and
biological fluids explains the failure of prior studies to detect
these isoforms.
Dephosphorylation of IGFBP-1 is accompanied by a sig-
nificant change in its binding affinity for IGF-I. The molec-
ular mechanism accounting for this change remains to be
defined. Our observation that the phosphorylated isoforms of
IGFBP-1 migrate faster in a non-SDS-containing polyacryl-
amide gel than does the nonphosphorylated form suggests
either that the phosphate groups contribute significantly to
the molecular charge of the protein or that phosphorylation
results in conformational changes that are neutralized in the
presence ofSDS. Such conformational changes, or local ionic
or steric interactions in the region of the IGF binding site,
might explain the 4- to 6-fold higher affinity of the phospho-
rylated form for IGF-I. A precedent for such an effect of
phosphorylation comes from studies of basic fibroblast
growth factor (bFGF). Phosphorylation of bFGF in its re-
ceptor-binding domain by cAMP-dependent protein kinase
results in an increased affinity of the phosphorylated bFGF
for the FGF receptor (21).
The biologic significance of the phosphorylation-
dependent increase in the affinity of IGFBP-1 for IGF-1 has
not been determined. IGFBP-1 preparations that contain
predominantly phosphorylated forms inhibit the cell growth
response to IGF-I. Likewise, IGFBP-l can inhibit IGF-I-
stimulated growth and other cellular functions, such as amino
acid transport (3, 4). Since the affinity of the phosphorylated
form of IGFBP-1 for IGF-I (Ka - 1010) is greater than that of
the IGF type 1 receptor (Ka 109), it is possible that it acts
by inhibiting receptor interaction. Because we have shown
that multimerization of IGFBP-1 is associated with its ca-
pacity to potentiate cellular responses to IGF-I (7), it is also
possible that phosphorylation could prevent the intermolec-
ular disulfide bond formation that leads to multimerization.
Only serine residues in IGFBP-1 appear to be phosphoryl-
ated, but it is not known which serine residues are the site(s)
of phosphorylation. Since there are four or five phosphoryl-
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exist. Given the effect phosphorylation has on IGF-I binding
affinity, it is also likely that at least one of the phosphory-
lation sites is in the vicinity of the IGF binding region. We
have not determined which of the phosphorylated isoforms
are responsible for the increased affinity.
The phosphorylation of intracellular proteins is a well-
recognized step in multiple cellular metabolic and signaling
pathways; however, the phosphorylation of secreted proteins
has only recently been investigated. Several proteins found in
the extracellular matrix have been shown to exist in phos-
phorylated forms. Osteopontin was first identified as a bone
matrix phosphorylated glycoprotein involved with cell adhe-
sion. It contains the cell attachment sequence Arg-Gly-Asp
(RGD) that is recognized by the integrin family of cell surface
receptors (22). The phosphorylated form of osteopontin binds
to cells in a heat-stable complex with multimerized fibronec-
tin on the cell surface, while the nonphosphorylated form
binds preferentially to soluble fibronectin (23, 24). These
findings suggest that phosphorylation of osteopontin has a
role in altering cell-matrix interactions. Fibrinogen and vit-
ronectin are other RGD-containing proteins that are phos-
phorylated on serine residues (25, 26). One-fourth of plasma
fibrinogen is phosphorylated in human adults at steady state,
but under acute stress conditions and in fetal plasma the
relative proportions of phosphorylated fibrinogen increases
(27). Phosphorylation of fibrinogen in vitro results in de-
creased susceptibility to plasmin digestion (28) and increased
fiber thickness in fibrin clots (29), again suggesting a physi-
ologic function for phosphorylation. The serine phosphory-
lation of osteopontin, vitronectin, and fibrinogen may be
relevant to phosphorylation of IGFBP-1, because IGFBP-1
contains the RGD sequence (11) and can be detected in the
extracellular matrix (unpublished findings).
Our studies show that phosphorylated IGFBP-1 is present
in cell lysates (Fig. 1) and that an ectokinase is not respon-
sible for its phosphorylation (Fig. 2). These results suggest
that IGFBP-1 is secreted after phosphorylation by an intra-
cellular kinase(s). This is analogous to fibrinogen, which is
secreted from the liver primarily as a phosphoprotein (30, 31).
However, 75% of plasma fibrinogen is dephosphorylated.
The sites and regulation of its dephosphorylation, as well as
the phosphatase responsible, are unknown. Our results show
that IGFBP-1 found in fetal serum and amniotic fluid is
relatively nonphosphorylated when compared with that in
hepatoma or decidual cell conditioned medium. This suggests
that in a similar fashion IGFBP-1, after its secretion as a
phosphoprotein, becomes partially dephosphorylated in
vivo. We have been unable to affect the phosphorylation of
IGFBP-1 by cells in culture with IGF-I, insulin, or modula-
tors of either cAMP-dependent protein kinase or protein
kinase C. Phosphorylation of IGFBP-1 may be constitutively
active and not under tight regulatory control. It may be that
dephosphorylation of IGFBP-1 occurring after secretion is a
more highly regulated and physiologically important event
than phosphorylation.
Because amniotic fluid contains both phosphorylated and
nonphosphorylated IGFBP-1, the two forms of IGFBP-1 that
were described in an earlier report (6) to have identical
mobility in SDS-containing gels but different elution patterns
from DEAE-cellulose may have differed only with regard to
phosphorylation. If true, this finding is likely to be biologi-
cally significant. The form that was previously shown to be
eluted from DEAE-cellulose at lower ionic strength could
represent the nonphosphorylated form. This form potenti-
ated the effect of IGF-I in stimulating DNA synthesis (6) and
multimerized (7). Conversely, an additional form that re-
quired higher ionic strength for elution (phosphorylated
IGFBP-1) neither potentiated IGF-I action nor formed mul-
timers. In addition, we have observed that recombinant,
nonphosphorylated IGFBP-1 potentiates the effects of IGF-I
on thymidine incorporation, while the mixture of phospho-
rylated isoforms of IGFBP-1 from HepG2 cells does not
(unpublished observations). The state of phosphorylation of
IGFBP-1 therefore may be an important determinant of its
biologic activity.
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